Left arrow icon
Left arrow icon
Left arrow icon

We expect more for those who matter most: patients

Millions of people suffer from chronic autoimmune and inflammatory diseases. At DICE, we understand that currently available medicines for these diseases can be invasive and inaccessible.


We are Committed

to developing convenient, oral medicines for a variety of immunological conditions. We study our innovative oral therapeutics in clinical trials with the goal of making them available to patients in need as rapidly as possible.

Clinical Trials

0 1


We are conducting a Phase 1 trial with DC-806 designed to generate safety and pharmacokinetic data, as well as provide early clinical proof-of-concept in psoriasis patients. The trial is being conducted in three overlapping cohorts: Phase 1a (single ascending dose) and Phase 1b (multiple ascending dose) in healthy volunteers, and a proof-of-concept Phase 1c in psoriasis patients.